Zhi Tong Cai Jing·2025-11-03 02:01Core Viewpoint - The stock of药捷安康-B (02617) opened over 6% higher following the announcement of a collaboration agreement with Neurocrine Biosciences to develop NLRP3 inhibitors for various diseases, indicating positive market sentiment towards the partnership [1] Group 1: Partnership Details - On November 3,药捷安康-B announced a licensing and research collaboration agreement with Neurocrine Biosciences, Inc. to develop NLRP3 inhibitors [1] - Neurocrine has been granted exclusive rights to develop, manufacture, and commercialize the NLRP3 drug platform outside Greater China, while the company retains rights within Greater China [1] - The agreement has a total potential value of $881.5 million, including upfront payments and milestone payments related to development and commercialization progress [1] Group 2: Market Reaction - Following the announcement, the stock price of药捷安康-B rose by 6.58%, reaching HKD 195.9, with a trading volume of HKD 6.5627 million [1]